Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with a focus on addressing these challenges for the new sickle cell disease (SCD) therapies, Casgevy and Lyfgenia.
Share the research